METHODS: 47 patients with OCD were enrolled. They were randomly allocated to active or sham stimulation groups, and underwent HD-tDCS stimulation treatment for 2 weeks. The central electrode located in the right orbitofrontal cortex region was cathodic. The severity of the patients\' obsessive-compulsive symptoms, depression and anxiety were assessed before and after treatment.
RESULTS: Out of the total, 44 patients concluded the treatment, comprising 23 participants from the active stimulation group and 21 from the sham stimulation group. Notably, substantial reductions in symptoms related to OCD, depression, and anxiety were exhibited in both groups. With a response rate of 26.1% in the active stimulation group and 23.8% in the sham stimulation group, there was no significant difference in efficacy observed. Furthermore, the reduction in depression and anxiety symptoms at the conclusion of the treatment was not notably superior in the active stimulation group.
CONCLUSIONS: This study provided evidence for the acceptability and safety of HD-tDCS. Nevertheless, the study did not reveal notable clinical effectiveness of tDCS in addressing moderate to severe OCD in comparison to the sham stimulation group.
方法:纳入47例强迫症患者。他们被随机分配到活动或假刺激组,行HD-tDCS刺激治疗2周。位于右眶额叶皮质区域的中心电极为阴极。患者强迫症状的严重程度,在治疗前后评估抑郁和焦虑。
结果:在总数中,44例患者结束治疗,包括23名来自主动刺激组的参与者和21名来自假刺激组的参与者。值得注意的是,与强迫症相关的症状大幅减少,抑郁症,两组均表现出焦虑。主动刺激组有效率为26.1%,假刺激组有效率为23.8%。观察到的疗效没有显着差异。此外,治疗结束时抑郁和焦虑症状的减轻在主动刺激组中并不显著优于对照组.
结论:本研究为HD-tDCS的可接受性和安全性提供了证据。然而,与假刺激组相比,该研究未显示tDCS在治疗中度至重度OCD方面的显著临床有效性.